Belimumab is under clinical development by GSK and currently in Phase II for Emphysema. According to GlobalData, Phase II drugs for Emphysema have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Belimumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Belimumab overview
Belimumab (Benlysta) is a human IgG1 monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BlyS), acts as immunosuppressant agent. It is formulated as Lyophilized powder for solution and solution for intravenous and subcutaneous route of administration. Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g positive anti-dsDNA and low complement) despite standard therapy, and for the treatment of systemic lupus erythematosus inadequately treated with existing treatments in pediatrics, as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity in children of five years and older. Benlysta is also indicated for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Benlysta is indicated for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy.
Belimumab is under development for the treatment of relapsed and refractory chronic lymphocytic leukemia (CLL), persistent or chronic immune thrombocytopenia (ITP), cryoglobulinemia vasculitis (CV), hyperthyroid Graves' disease (GD), relapsing remitting multiple sclerosis and active orbitopathy (GO), diffuse cutaneous systemic sclerosis, and globally (overseas),idiopathic inflammatory myositis, active lupus nephritis, pulmonary emphysema, chronic graft-versus-host disease and lupus nephritis.
It was also under development for the treatment of rheumatoid arthritis, Waldenstrom's macroglobulinemia, vasculitis including ANCA associated vasculitis (granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis, idiopathic thrombocytopenic purpura, idiopathic/primary membranous nephropathy, myasthenia gravis, primary Sjögren’s syndrome and prevention of kidney transplant rejection.
For a complete picture of Belimumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
